
CAS 2089288-03-7
:Fórmula:C27H32FN5O2
InChI:InChI=1S/C27H32FN5O2/c1-18(2)33-26-21-14-20(22(28)15-23(21)29-17-24(26)31(3)27(33)34)19-8-9-25(30-16-19)35-13-7-12-32-10-5-4-6-11-32/h8-9,14-18H,4-7,10-13H2,1-3H3
Chave InChI:VQSZIPCGAGVRRP-UHFFFAOYSA-N
SMILES:CC(C)N1C2=C(C=NC3=CC(=C(C=C32)C4=CN=C(C=C4)OCCCN5CCCCC5)F)N(C1=O)C
Filtrar por
Percentagem de pureza
0
100
|
0
|
50
|
90
|
95
|
100
Foram encontrados 8 produtos.
- Preços em ordem crescente
- Preços em ordem decrescente
- Menor grau de pureza
- Maior grau de pureza
- Estimativa de entrega mais rápida
azd1390
CAS:AZD1390: Potent ATM inhibitor (IC50: 0.78 nM), >10,000-fold selectivity vs. PIKK enzymes.Fórmula:C27H32FN5O2Pureza:97.41% - 99.72%Cor e Forma:White SolidPeso molecular:477.5737AZD1390
CAS:7-Fluoro-1-isopropyl-3-methyl-8-(6-(3-(piperidin-1-yl)propoxy)pyridin-3-yl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-oneFórmula:C27H32FN5O2Pureza:98%Peso molecular:477.57AZD1390
CAS:AZD1390 is a positron-emitting drug that can be used to study the molecular mechanisms of cancer. It binds to receptors on the surface of cells, activating cell signaling pathways, and is currently being studied for use in the treatment of squamous carcinoma. AZD1390 is able to penetrate solid tumours and it has been found to be effective against some types of cancer. The clinical studies showed that AZD1390 was safe and well-tolerated in patients with advanced cancers and that it had an acceptable side effect profile. This drug also has pharmacokinetic properties which make it suitable as a therapeutic agent.Fórmula:C27H32FN5O2Pureza:Min. 95%Peso molecular:477.57 g/mol







